[1]刘自威,朱华强,王洋.程序性死亡蛋白-1抑制剂联合化学治疗方案治疗非小细胞肺癌疗效观察[J].新乡医学院学报,2022,39(10):948-953.[doi:10.7683/xxyxyxb.2022.10.009]
　LIU Ziwei,ZHU Huaqiang,WANG Yang.Effect of programmed death protein-1 inhibitor combined with chemotherapy regimen in the treatment of non-small cell lung cancer[J].Journal of Xinxiang Medical University,2022,39(10):948-953.[doi:10.7683/xxyxyxb.2022.10.009]
点击复制

程序性死亡蛋白-1抑制剂联合化学治疗方案治疗非小细胞肺癌疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年10
页码:
948-953
栏目:
临床研究
出版日期:
2022-10-05

文章信息/Info

Title:
Effect of programmed death protein-1 inhibitor combined with chemotherapy regimen in the treatment of non-small cell lung cancer
作者:
刘自威; 朱华强; 王洋
（濮阳市第五人民医院肿瘤内科，河南　濮阳　457000）
Author(s):
LIU Ziwei; ZHU Huaqiang; WANG Yang
（Department of Oncology,the Fifth People′s Hospital of Puyang City,Puyang 457000,Henan Province,China）
关键词:
程序性死亡蛋白-1抑制剂; 非小细胞肺癌; 免疫功能; 细胞因子
Keywords:
programmed death protein-1 inhibitor; non-small cell lung cancer; immune function; cytokine
分类号:
R734.2
DOI:
10.7683/xxyxyxb.2022.10.009
文献标志码:
A
摘要:
目的　探讨程序性死亡蛋白-1（PD-1）抑制剂联合常规化学治疗对非小细胞肺癌（NSCLC）的治疗效果。 方法　选择2018年1月至2020年5月濮阳市第五人民医院收治的85例NSCLC患者为研究对象，根据治疗方法将患者分为对照组（n=42）和观察组（n=43）。对照组患者给予常规化学治疗，第1天静脉滴注卡铂0.3～0.4 g·m-2、紫杉醇脂质体135～175 mg·m-2、培美曲塞500 mg·m-2， 2l d为1个周期，1个周期给药1次，连续治疗6个周期。观察组患者在对照组治疗基础上给予PD-1抑制剂派姆单抗，静脉滴注，第1天2 mg·kg-1,21 d为1个周期，1个周期给药1次，连续治疗6个周期。治疗后，评估2组患者的临床疗效，并计算总有效率。分别于治疗前后，采用流式细胞术检测2组患者外周血中CD3+、CD4+、CD8+ T细胞及辅助性T（Th）1、Th2细胞水平，采用酶联免疫吸附试验检测2组患者血清中干扰素-γ（IFN-γ）、肿瘤坏死因子-α（TNF-α）、白细胞介素-10（IL-10）、白细胞介素-4（IL-4）水平。观察并记录2组患者治疗期间白细胞减少、中性粒细胞减少、恶心呕吐、腹泻、周围神经毒性、皮疹发生情况，并计算不良反应发生率。结果　治疗后，对照组患者部分缓解 25例，疾病稳定 14例，疾病进展3例，总有效率为59.52%（25/42）;观察组患者完全缓解1例，部分缓解 34例，疾病稳定7例，疾病进展 1例，总有效率为81.40%（35/43）。观察组患者的总有效率显著高于对照组（χ2=4.896，P<0.05）。治疗前，2组患者外周血中的CD3+、CD4+、CD8+ T细胞及Th1、Th2细胞水平比较差异无统计学意义（P>0.05）；2组患者治疗后的CD3+、CD4+T细胞及Th1、Th2细胞水平显著高于治疗前，CD8+ T细胞水平显著低于治疗前（P<0.05）；治疗后，观察组患者外周血中的CD3+ T细胞及Th1细胞水平显著高于对照组（P<0.05）；治疗后，观察组与对照组患者外周血中的CD4+、CD8+ T细胞及Th2细胞水平比较差异无统计学意义（P>0.05）。治疗前，2组患者血清中IFN-γ、TNF-α、IL-10、IL-4水平比较差异无统计学意义（P>0.05）；2组患者治疗后血清中TNF-α、IL-4水平显著低于治疗前，血清中IFN-γ、IL-10水平显著高于治疗前（P<0.05）；治疗后，观察组患者血清中IFN-γ水平显著高于对照组（P<0.05）；治疗后，2组患者血清中TNF-α、IL-10、IL-4水平比较差异无统计学意义（P>0.05）。治疗过程中，观察组与对照组患者白细胞减少、中性粒细胞减少、恶心呕吐、腹泻、周围神经毒性及皮疹的发生率比较差异无统计学意义（χ2=1.898、1.694、2.173、1.001、0.988、1.838，P>0.05）。结论　PD-1抑制剂联合常规化学治疗方案可能通过上调CD3+ T细胞、Th1细胞及血清IFN-γ水平发挥对NSCLC患者的抗肿瘤作用，临床疗效显著，可改善患者的免疫功能，降低炎症反应，且安全性好。
Abstract:
Objective　To investigate the effect of programmed death protein-1 (PD-1) inhibitor combined with conventional chemotherapy in the treatment of non-small cell lung cancer (NSCLC).Methods　A total of 85 NSCLC patients admitted to the Fifth People′s Hospital of Puyang City from January 2018 to May 2020 were selected as the research objects,and they were divided into the control group (n=42) and the observation group (n=43) according to the treatment method.The patients in the control group were given conventional chemotherapy,includingintravenous infusion of carboplatin 0.3-0.4 g·m-2,paclitaxel liposome 135-175 mg·m-2,pemetrexed 500 mg·m-2 on the first day,2l days as a cycle,once per a cycle,the treatment was continued for 6 cycles.The patients in the observation group were given the PD-1 inhibitor pembrolizumab on the basis of the treatment in the control group,intravenous drip,2 mg·kg-1 on the first day,21 days as a cycle,once per a cycle,and the treatment was continued for 6 cycles.After treatment,the clinical efficacy of patients in the two groups was evaluated,and the total effective rate was calculated.Before and after treatment,the levels of CD3+,CD4+,CD8+ T cells and helper T (Th) 1 and Th2 cells in peripheral blood of patients in the two groups were detected by the flow cytometry;the levels of interferon-γ (IFN-γ),tumor necrosis factor-α (TNF-α),interleukin-10 (IL-10) and interleukin-4 (IL-4) in serum of patients in the two groups were detected by enzyme-linked immunosorbent assay.The incidence of leukopenia,neutropenia,nausea and vomiting,diarrhea,peripheral neurotoxicity and rash of patients in the two groups were observed and recorded during treatment,and the incidences of adverse reactions were calculated.Results　After treatment,25 cases had partial remission,14 cases had stable disease,and 3 cases had progressive disease,with a total effective rate of 59.52% (25/42) in the control group;in the observation group,1 case had complete remission,34 cases had partial remission,7 cases had stable disease,and 1 case had disease progression,the total effective rate was 81.40% (35/43).The total effective rate of patients in the observation group was significantly higher than that in the control group (χ2=4.896,P<0.05).Before treatment,there was no significant difference in the levels of CD3+ T cells,CD4+ T cells,CD8+ T cells,Th1 cells and Th2 cells in peripheral blood of patients between the two groups (P>0.05).The levels of CD3+ T cells,CD4+ T cells and Th1 cells,Th2 cells in peripheral blood of patients in the two groups after treatment were significantly higher than those before treatment,and the level of CD8+ T cells was significantly lower than that before treatment (P<0.05);after treatment,the levels of CD3+ T cells and Th1 cells in peripheral blood of patients in the observation group were significantly higher than those in the control group (P<0.05);there was no significant difference in the levels of CD4+ T cells,CD8+ T cells and Th2 cells in peripheral blood of patients between the two groups after treatment (P>0.05).Before treatment,there was no significant difference in serum IFN-γ,TNF-α,IL-10 and IL-4 levels of patients between the two groups (P>0.05).The levels of serum TNF-α and IL-4 of patients after treatment were significantly lower than those before treatment,and the levels of serum IFN-γ and IL-10 of patients were significantly higher than those before treatment in the two groups (P<0.05).After treatment,the level of serum IFN-γ of patients in the observation group was significantly higher than that in the control group (P<0.05);there was no significant difference in serum TNF-α,IL-10 and IL-4 levels of patients between the two groups (P>0.05).During the treatment,there was no significant difference in the incidences of leukopenia,neutropenia,nausea and vomiting,diarrhea,peripheral neurotoxicity and rash of patients between the two group (χ2=1.898,1.694,2.173,1.001,0.988,1.838;P>0.05).Conclusion　PD-1 inhibitor combined with conventional chemotherapy may play an anti-tumor effect on NSCLC patients by up-regulating the levels of CD3+ T cells,Th1 cells and serum IFN-γ level,the clinical efficacy is significant,and it can improve patients′ immune function,reduce inflammatory response,and it is good safe.

参考文献/References:

［1］　SU Z,DIAS-SANTAGATA D,DUKE M,et al.A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer［J］.J Mol Diagn,2011,13(1):74-84.
［2］　ANTONIA S J,VILLEGAS A,DANIEL D,et al.Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer［J］.N Engl J Med,2017,377(20):1919-1929.
［3］　SORIA J C,OHE Y,VANSTEENKISTE J,et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer［J］.N Engl J Med,2018,378(2):113-125.
［4］　SONG P,ZHANG J,SHANG C,et al.Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors［J］.Sci Rep,2019,9(1):4278-4279.
［5］　TAKEUCHI M,DOI T,OBAYASHI K,et al.Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer［J］.Immunol Lett,2018,196(77):155-160.
［6］　宋鹏,尚聪聪,张力.PD-1/PD-L1抑制剂治疗中青年和高龄非小细胞肺癌患者有效性的Meta分析［J］.山西医科大学学报,2018,49(11):1334-1340.
SONG P,SHANG C C,ZHANG L.Efficacy of PD-1 / PD-L1 inhibitors in the treatment of younger versus elderly non-small cell lung cancer patients:a Meta-analysis［J］.J Shanxi Med Univ,2018,49(11):1334-1340.
［7］　白馨雅,张金梦,孙洋,等.免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用［J］.国际肿瘤学杂志,2019,46(8):500-504.
BAI X Y,ZHANG J M,SUN Y,et al.Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer ［J］.J Int Oncol,2019,46(8):500-504.
［8］　FIDLER M J,FHIED C L,RODER J,et al.The serum-based Veri-Strat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients［J］.BMC Cancer,2018,18(1):310.
［9］　SUI H,MA N,WANG Y,et al.Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer:toward personalized medicine and combination strategies［J］.J Immunol Res,2018,2018(1):e6984948.
［10］　［德］ 克瑞思田.非小细胞肺癌治疗［M］.钟文昭，吴一龙.北京：人民卫生出版社,2010:321-322.
CHRISTIAN M.Non-small cell lung cancer treatment［M］.ZHONG W Z,WU Y L.Beijing:People′s Health Publishing House,2010:321-322.
［11］　ARBOUR K C,LUU A T,LUO J,et al.Deep learning to estimate RECIST in patients with nsclc treated with PD-1 blockade［J］.Cancer Discov,2021,11(1):59-67.
［12］　MEYERS D E,BRYAN P M,BANERJI S,et al.Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer［J］.Curr Oncol,2018,25(4):e324-e334.
［13］　王钰聪,徐英辉,李宏伟,等.PD1/PD-L1免疫检查点抑制剂治疗非小细胞肺癌的研究进展［J］.吉林大学学报(医学版),2019,45(4):965-970.
WANG Y C,XU Y H,LI H W,et al.Research progress of PD1/ PD-L1 immune checkpoint inhibitor in the treatment of non-small cell lung cancer［J］.J Jilin Univ (Medical Edition),2019,45 (4):965-970.
［14］　肖文璐.调节性T细胞在肿瘤免疫中作用机制及治疗新策略的研究进展［J］.中国肿瘤生物治疗杂志,2019,26(12):1387-1391.
XIAO W L.Progress in the research mechanism of regulatory T cells in tumor immunity and new therapeutic strategies［J］.Chin J Cancer Biother,2019,26 (12):1387-1391.
［15］　张佳.PD-1/PD-L1抑制剂联合EGFR-TKIs对非小细胞肺癌治疗的研究进展［J］.重庆医学,2019,48(15):2650-2653,2657.
ZHANG J.Research progress of PD-1/PD-L1 inhibitor combined with EGFR TKIs in the treatment of non-small cell lung cancer［J］.Chongqing Med J,2019,48 (15):2650-2653,2657.
［16］　CALIFANO R,LAL R,LEWANSKI C,et al.Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer:implications for clinical practice［J］.Future Oncol,2018,14(23):2415-2431.
［17］　 王守正,李峻岭.PD-1/PD-L1抑制剂治疗晚期非小细胞肺癌疗效预测的研究进展［J］.癌症进展,2017,15(6):618-622.
WANG S Z,LI J L.Research progress of PD-1/PD-L1 inhibitor in predicting the efficacy of advanced non-small cell lung cancer［J］.Cancer Progress,2017,15 (6):618-622.
［18］　XU B,ZHANG H,WANG Y,et al.Mechanism of Xu Li′s experiential prescription for the treatment of EGFR-positive NSCLC［J］.Evid Based Complement Alternat Med,2020,2020:8787153.
［19］　KAANANE H,SENHAJI N,BERRADI H,et al.The influence of interleukin-6,interleukin-8,interleukin-10,interleukin-17,TNF-A,MIF,STAT3 on lung cancer risk in moroccan population［J］.Cytokine,2022,151(8):e155806.
［20］　COMES T S,ABRIL V P,SNCHEZ J G,et al.112P impact of clinical parameters on CD8 and CD4 lymphocyte distribution in patients with non-small cell lung cancer (NSCLC)［J］.Annals Oncol,2020,31(3):e286.
［21］　ZHAO Q,BI Y,SUN H,et al.Serum IL-5 and IFN-γ are novel predictive biomarkers for anti-PD-1 treatment in NSCLC and GC patients［J］.Dis Markers,2021,2021:5526885.
［22］　戴春,周永春,黄云超,等.非小细胞肺癌患者血清中细胞因子(IL-2、IL-4、IL-6、IL-10)的含量与临床分期的关系［J］.现代肿瘤医学,2015,23(6):779-781.
DAI C,ZHOU Y C,HUAGN Y C,et al.Relationship between cytokines(IL-2,IL-4,IL-6,IL-10) and clinical stage in non-small cell lung cancer patients［J］.J Mod Oncol,2015,23(6):779-781.
［23］　宁红娟,杨小花.吉西他滨联合卡铂对肺癌患者血清IL-2、IFN-γ、 TNF-α与IGF-1水平的影响［J］.实用癌症杂志,2018,33(12):2008-2010.
NING H J,YANG X H.Effects of gemcitabine combined with carboplatin on serum levels of IL-2,IFN-γ,TNF-α and IGF-1 in patients with lung cancer［J］.Pract J Cancer,2018,33(12):2008-2010.
［24］　 包晓燕,陈飞,金铁峰,等.PD-1/PD-L1抑制剂在晚期NSCLC免疫治疗中的应用研究进展［J］.浙江医学,2019,41(2):202-206.
BAO X Y,CHEN F,JIN T F,et al.Progress in the application of PD-1/PD-L1 inhibitors in immunotherapy of advanced NSCLC ［J］.Zhejiang Med Science,2019,41(2):202-206.
［25］　CHEN X,GAO A,ZHANG F,et al.ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation［J］.Theranostics,2021,11(7):3392-3416.

相似文献/References:

[1]张开普.介入治疗局部晚期非小细胞肺癌42例[J].新乡医学院学报,2002,19(05):421.
[2]牛红蕊,袁 亮,吴随群.羟基喜树碱联合顺铂和足叶乙甙治疗中晚期非小细胞肺癌39例[J].新乡医学院学报,2002,19(05):419.
[3]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌l7例[J].新乡医学院学报,2003,20(02):126.
[4]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌17 例[J].新乡医学院学报,2003,20(02):126.
[5]张海君,闫卫东,邝先奎.目的从伦理学的角度来思考基因歧视产生的原因和所引起的危害，并寻求对策。方法查阅并分析近1O年的文献。结果导致基因歧视产生的理论观点是不正确的，这种现象对人类有极大的危害，人们可以通过对隐私权的保护来避免或减轻它对人类的伤害。结论 基因歧视是不公正也是不[J].新乡医学院学报,2003,20(06):428.
[6]杨廷桐,李秀杰,武俊芳,等.端粒酶反转录酶活化与p53金属蛋白酶-9表达对非小细胞肺癌发生的影响[J].新乡医学院学报,2007,24(05):000.
[7]杨廷桐,武俊芳,李秀杰,等.非小细胞肺癌中p14ARF和mtp53蛋白表达与临床病理参数的关系[J].新乡医学院学报,2008,25(04):336.
[8]姬明丽,千智斌,徐自超.p53蛋白与非小细胞肺癌多药耐药性的关系[J].新乡医学院学报,2008,25(01):013.
[9]孙秀威,陈玉玲,黄鹏.非小细胞肺癌中核糖核苷酸还原酶亚单位M1 表达及其与吉西他滨化学治疗敏感性相关研究[J].新乡医学院学报,2011,28(02):157.
[10]郑翠侠,韩兵,周翔,等.非小细胞肺癌中表皮生长因子受体基因突变的筛查[J].新乡医学院学报,2011,28(02):190.

更新日期/Last Update: 2022-10-05